apixaban,enoxaparin
bms,pfizer
['freedom covid', 'cardio']
based on the results from freedom covid trial presented at #acc23/#wccardio, therapeutic-dose anticoagulation shows no significant composite risk reduction for noncritical, hospitalized #covid19 patients. more: #cvcoag #cardiotwitter 
Official American College of Cardiology account. Join us to transform cardiovascular care & improve heart health. Find us: @JACCJournals @Cardiology